Skip to main content
Log in

Cimetidine-phenytoin interaction: Effect on serum phenytoin concentration and antipyrine test

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

In a prospective study in nine patients the effects of phenytoin and of cimetidine (1000mg/day) + phenytoin on the antipyrine test and serum phenytoin concentrations were studied. Serum phenytoin increased from the steady state level of 5.7±1.3 mg/l to 9.1±1.4mg/l after three weeks on cimetidine (p<0.01), and fell to 5.8±1.2 mg/l within two weeks after withdrawal of cimetidine. The protein binding of phenytoin was not changed by cimetidine. After use of phenytoin for 2–4 months, antipyrine clearance increased from 0.67±0.06ml/min/kg to 1.61±0.22 ml/ min/kg, and antipyrine half-live fell from 10.9±1.3h to 4.5±0.6h as compared to the values before phenytoin treatment (p<0.01). After three weeks combined use of cimetidine and phenytoin, antipyrine clearance was decreased to 1.01±0.07 ml/min/kg and antipyrine half-life was prolonged to 6.1±0.5h, (p<0.01) compared to the values on phenytoin alone. The distribution volume of antipyrine was not affected by phenytoin nor by cimetidine + phenytoin. The half-life of cimetidine was 2.8±0.3h in the patients on longterm phenytoin treatment. There was a significant positive correlation (p<0.001) between the increase in serum phenytoin concentration and the prolongation of antipyrine half-life caused by cimetidine. Thus, cimetidine increases serum phenytoin concentration, very probably by inhibiting its metabolism. Care should be taken in the concomitant use of cimetidine and phenytoin, and the dose of phenytoin should be modified according to the clinical symptoms and serum phenytoin concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Richens A (1976) Drug interactions. In: Richens A (ed) Drug treatment of epilepsy. Kimpton, London, pp 105–117

    Google Scholar 

  2. Neuvonen PJ, Lehtovaara R, Bardy A, Elomaa E (1979) Antipyretic analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol 15:263–268

    Google Scholar 

  3. Lunde PKM, Rane A, Yaffe SJ, Lund L, Sjöqvist F (1970) Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther 11:846–855

    Google Scholar 

  4. Fraser DG, Ludden TM, Evens RP, Sutherland EW (1980) Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 27:165–169

    Google Scholar 

  5. Neuvonen PJ, Lehtovaara R, Bardy A (1980) Effect of some gastrointestinal factors on serum phenytoin concentration. In: Johannessen SI et al. (eds) Antiepileptic therapy: Advances in drug monitoring. Raven Press, New York, pp 149–156

    Google Scholar 

  6. Freston JW (1978) Cimetidine in the treatment of gastric ulcer. Review and commentary. Gastroenterology 74:426–430

    Google Scholar 

  7. Winship DH (1978) Cimetidine in the treatment of duodenal ulcer. Review and commentary. Gastroenterology 74:402–406

    Google Scholar 

  8. Flind AC (1978) Cimetidine and oral anticoagulants. Br Med J 2:1367

    Google Scholar 

  9. Silver BA, Bell WR (1979) Cimetidine potentiation of the hypoprothrombinaemic effect of warfarin. Ann Intern Med 90:348–49

    Google Scholar 

  10. Serlin MJ, Sibeon RG, Mossman S, Breckenridge AM, Williams JRB, Atwood JL, Willoughby JMT (1979) Cimetidine: Interaction with oral anticoagulants in man. Lancet 2:317–319

    Google Scholar 

  11. Klotz U, Anttila V-J (1980) Drug interactions with cimetidine: Pharmacokinetic studies to evaluate its mechanism. Naunyn-Schmiedeberg's Arch Pharmacol 311 (Suppl) R 77

    Google Scholar 

  12. Puurunen J, Sotaniemi E, Pelkonen O (1979) Cimetidine inhibits microsomal drug metabolism in man. Naunyn-Schmiedeberg's Arch Pharmacol 308 (Suppl) R 24

    Google Scholar 

  13. Fisher P, House F, Inns P, Morrison PJ, Rogers HJ, Bradbrook ID (1980) Effect of cimetidine on the absorption of orally administered tetracycline. Br J Clin Pharmacol 9:153–158

    Google Scholar 

  14. Neuvonen PJ, Tokola RA, Kaste M (1980) Cimetidine-phenytoin interaction: Effect on serum phenytoin concentration and antipyrine test in man. Naunyn-Schmiedeberg's Arch Pharmacol 313: (Suppl) R 60

    Google Scholar 

  15. Ehrnebo M, Agurell S, Boréus LE, Gordon E, Lönroth U (1974) Pentazocine binding to blood cells and plasma proteins. Clin Pharmacol Ther 16:426–429

    Google Scholar 

  16. Berlin A, Agurell S, Borgå O, Lund L, Sjöqvist F (1972) A micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid — a comparison between a gas chromatographic and a spectrophotometric method. Scand J Clin Lab Invest 29:281–287

    Google Scholar 

  17. Prescott LF, Adjepon-Yamoah KK, Roberts E (1973) Rapid gas-liquid chromatography estimation of antipyrine in plasma. J Pharm Pharmacol 25:205–207

    Google Scholar 

  18. Randolph WC, Osborne VL, Walkenstein SS, Intoccia AP (1977) High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-receptor antagonist, in blood and urine. J Pharm Sci 66:1148–1150

    Google Scholar 

  19. Duncan DB (1955) Multiple range and multiple F tests. Biometrics 11:1–42

    Google Scholar 

  20. Puurunen J, Pelkonen O (1979) Cimetidine inhibits microsomal drug metabolism in the rat. Eur J Pharmacol 55:335–336

    Google Scholar 

  21. Neuvonen PJ (1979) Bioavailability of phenytoin: Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 4:91–103

    Google Scholar 

  22. Neuvonen PJ, Pentikäinen PJ, Elfving SM (1977) Factors affecting the bioavailability of phenytoin. Int J Clin Pharmacol 15:84–89

    Google Scholar 

  23. Vesell ES (1979) The antipyrine test in clinical pharmacology: Conceptions and misconceptions. Clin Pharmacol Ther 26:275–286

    Google Scholar 

  24. Sultatos LG, Dvorchik BH, Vesell ES, Shand DG, Branch RA (1980) Further observations on relationships between antipyrine half-life, clearance and volume of distribution: An appraisal of alternative kinetic parameters used to assess the elimination of antipyrine. Clin Pharmacokinet 5:263–273

    Google Scholar 

  25. Somogyi A, Rohner H-G, Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 5:84–94

    Google Scholar 

  26. Edmonds ME, Ashford RFU, Brenner MK, Saunders A (1979) Cimetidine: does neurotoxicity occur? Report of three cases. J R Soc Med 72:172

    Google Scholar 

  27. Schentag JJ, Cerra FB, Calleri G, De Glopper E, Rose JQ, Bernhard H (1979) Pharmacokinetic and clinical studies with cimetidine-associated mental confusion. Lancet 1:177

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neuvonen, P.J., Tokola, R.A. & Kaste, M. Cimetidine-phenytoin interaction: Effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol 21, 215–220 (1981). https://doi.org/10.1007/BF00627923

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00627923

Key words

Navigation